Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

David Ternant (1) , Zahir Berkane (2) , Laurence Picon (3) , Valérie Gouilleux-Gruart (1) , Jean-Frédéric Colombel (4) , Matthieu Allez (5) , Edouard Louis (6) , Gilles Paintaud (1)

1 GICC UMR 7292 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017]
2 UGA UFRP - Université Grenoble Alpes - UFR Pharmacie
3 LMD - Laboratoire de Météorologie Dynamique (UMR 8539)
4 MSSM - Icahn School of Medicine at Mount Sinai [New York]
5 INSERM, U1160, Département de Gastroentérologie
6 GIGA-Research - Groupe Interdisciplinaire de Génoprotéomique Appliquée

Infliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody that profoundly modified the treatment of Crohn's disease (CD). The polymorphism of Fc fragment of IgG, low affinity IIIa, receptor (CD16a) [FCGR3A] influences the biological response to infliximab in patients with CD. Our aim was to study its influence on infliximab pharmacokinetics and risk of relapse after infliximab discontinuation.

Domains: Life Sciences [q-bio]

David Ternant, Zahir Berkane, Laurence Picon, Valérie Gouilleux-Gruart, Jean-Frédéric Colombel, et al.. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease. Clinical Pharmacokinetics, 2015, 54 (5), pp.551-562. ⟨10.1007/s40262-014-0225-3⟩. ⟨hal-02425490⟩